Abstract
The aim of this investigation was to develop a mechanism-based pharmacokinetic–pharmacodynamic (PK–PD) model for the biological system prolactin response following a dopamine inhibition challenge using remoxipride as a paradigm compound. After assessment of baseline variation in prolactin concentrations, the prolactin response of remoxipride was measured following (1) single intravenous doses of 4, 8 and 16 mg/kg and (2) following double dosing of 3.8 mg/kg with different time intervals. The mechanistic PK–PD model consisted of: (i) a PK model for remoxipride concentrations in brain extracellular fluid; (ii) a pool model incorporating prolactin synthesis, storage in lactotrophs, release into- and elimination from plasma; (iii) a positive feedback component interconnecting prolactin plasma concentrations and prolactin synthesis; and (iv) a dopamine antagonism component interconnecting remoxipride brain extracellular fluid concentrations and stimulation of prolactin release. The most important findings were that the free brain concentration drives the prolactin release into plasma and that the positive feedback on prolactin synthesis in the lactotrophs, in contrast to the negative feedback in the previous models on the PK–PD correlation of remoxipride. An external validation was performed using a dataset obtained in rats following intranasal administration of 4, 8, or 16 mg/kg remoxipride. Following simulation of human remoxipride brain extracellular fluid concentrations, pharmacodynamic extrapolation from rat to humans was performed, using allometric scaling in combination with independent information on the values of biological system specific parameters as prior knowledge. The PK–PD model successfully predicted the system prolactin response in humans, indicating that positive feedback on prolactin synthesis and allometric scaling thereof could be a new feature in describing complex homeostatic mechanisms.
Similar content being viewed by others
References
Petty RG (1999) Prolactin and antipsychotic medications: mechanism of action. Schizophr Res 35(Suppl):S67–S73
Movin-Osswald G, Hammarlund-Udenaes M (1995) Prolactin release after remoxipride by an integrated pharmacokinetic–pharmacodynamic model with intra- and interindividual aspects. J Pharmacol Exp Ther 274:921–927
Freeman ME, Kanyicska B, Lerant A, Nagy G (2000) Prolactin: structure, function, and regulation of secretion. Physiol Rev 80:1523–1631
Bagli M, Suverkrup R, Quadflieg R, Hoflich G, Kasper S, Moller HJ, Langer M, Barlage U, Rao ML (1999) Pharmacokinetic–pharmacodynamic modeling of tolerance to the prolactin-secreting effect of chlorprothixene after different modes of drug administration. J Pharmacol Exp Ther 291:547–554
Friberg LE, Vermeulen AM, Petersson KJF, Karlsson MO (2008) An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatment. Clin Pharmacol Ther 85:409–417
Ma G, Friberg LE, Movin-Osswald G, Karlsson MO (2010) Comparison of the agonist-antagonist interaction model and the pool model for the effect of remoxipride on prolactin. Br J Clin Pharmacol 70:815–824
Danhof M, De Jongh J, De Lange EC, Della PO, Ploeger BA, Voskuyl RA (2007) Mechanism-based pharmacokinetic–pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu Rev Pharmacol Toxicol 47:357–400
Ploeger BA, Van der Graaf PH, Danhof M (2009) Incorporating receptor theory in mechanism-based pharmacokinetic–pharmacodynamic (PK–PD) modeling. Drug Metab Pharmacokinet 24:3–15
Gabrielsson J, Green AR (2009) Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology. J Pharmacol Exp Ther 331:767–774
Danhof M, De Lange EC, Della Pasqua OE, Ploeger BA, Voskuyl RA (2008) Mechanism-based pharmacokinetic–pharmacodynamic (PK–PD) modeling in translational drug research. Trends Pharmacol Sci 29:186–191
De Lange EC, De Boer AG, Breimer DD (2000) Methodological issues in microdialysis sampling for pharmacokinetic studies. Adv Drug Deliv Rev 45:125–148
Yassen A, Olofsen E, Kan J, Dahan A, Danhof M (2007) Animal-to-human extrapolation of the pharmacokinetic and pharmacodynamic properties of buprenorphine. Clin Pharmacokinet 46:433–447
Zuideveld KP, Van der Graaf PH, Peletier LA, Danhof M (2007) Allometric scaling of pharmacodynamic responses: application to 5-ht1a receptor mediated responses from rat to man. Pharm Res 24:2031–2039
Boxenbaum H (1982) Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 10:201–227
Stevens J, Ploeger BA, Van der Graaf PH, Danhof M, De Lange EC (2011) Systemic and direct nose-to-brain transport pharmacokinetic model for remoxipride after intravenous and intranasal administration. Drug Metab Dispos 39:2275–2282
Stevens J, Suidgeest E, Van der Graaf PH, Danhof M, De Lange EC (2009) A new minimal-stress freely-moving rat model for preclinical studies on intranasal administration of CNS drugs. Pharm Res 26:1911–1917
Stevens J, Van den Berg D-J, De Ridder S, Niederlander HAG, Van der Graaf PH, Danhof M, De Lange ECM (2010) Online solid phase extraction with liquid chromatography-tandem mass spectrometry to analyze remoxipride in small plasma-, brain homogenate-, and brain microdialysate samples. J Chromatogr B 878:969–975
Gisleskog PO, Karlsson MO, Beal SL (2002) Use of prior information to stabilize a population data analysis. J Pharmacokinet Pharmacodyn 29:473–505
Mohell N, Sallemark M, Rosqvist S, Malmberg A, Hogberg T, Jackson DM (1993) Binding characteristics of remoxipride and its metabolites to dopamine d2 and d3 receptors. Eur J Pharmacol 238:121–125
Chi HJ, Shin SH (1978) The effect of exposure to ether on prolactin secretion and the half-life of endogenous prolactin in normal and castrated male rats. Neuroendocrinology 26:193–201
Post TM, Freijer JI, Ploeger BA, Danhof M (2008) Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn 35:185–202
Abelo A, Eriksson UG, Karlsson MO, Larsson H, Gabrielsson J (2000) A turnover model of irreversible inhibition of gastric acid secretion by omeprazole in the dog. J Pharmacol Exp Ther 295:662–669
Ben Jonathan N, LaPensee CR, LaPensee EW (2008) What can we learn from rodents about prolactin in humans? Endocr Rev 29:1–41
Phelps CJ (1986) Immunocytochemical analysis of prolactin cells in the adult rat adenohypophysis: distribution and quantitation relative to sex and strain. Am J Anat 176:233–242
Dada MO, Campbell GT, Blake CA (1984) Pars distalis cell quantification in normal adult male and female rats. J Endocrinol 101:87–94
Asa SL, Penz G, Kovacs K, Ezrin C (1982) Prolactin cells in the human pituitary. A quantitative immunocytochemical analysis. Arch Pathol Lab Med 106:360–363
Utama FE, Tran TH, Ryder A, LeBaron MJ, Parlow AF, Rui H (2009) Insensitivity of human prolactin receptors to nonhuman prolactins: relevance for experimental modeling of prolactin receptor-expressing human cells. Endocrinology 150:1782–1790
Kohler C, Radesater AC, Karlsson-Boethius G, Bryske B, Widman M (1992) Regional distribution and in vivo binding of the atypical antipsychotic drug remoxipride. A biochemical and autoradiographic analysis in the rat brain. J Neural Transm Gen Sect 87:49–62
Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998) Dopamine receptors: from structure to function. Physiol Rev 78:189–225
Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, Nash NR, Olsson R, Davis RE, Hacksell U, Weiner DM, Brann MR (2005) Intrinsic efficacy of antipsychotics at human d2, d3, and d4 dopamine receptors: identification of the clozapine metabolite n-desmethylclozapine as a d2/d3 partial agonist. J Pharmacol Exp Ther 315:1278–1287
Perello M, Chacon F, Cardinali DP, Esquifino AI, Spinedi E (2006) Effect of social isolation on 24-h pattern of stress hormones and leptin in rats. Life Sci 78:1857–1862
Featherstone K, White MR, Davis JR (2012) The prolactin gene: a paradigm of tissue-specific gene regulation with complex temporal transcription dynamics. J Neuroendocrinol 24:977–990
Widman M, Nilsson LB, Bryske B, Lundstrom J (1993) Disposition of remoxipride in different species. Species differences in metabolism. Arzneimittelforschung 43:287–297
Farde L, Von Bahr C (1990) Distribution of remoxipride to the human brain and central d2-dopamine receptor binding examined in vivo by pet. Acta Psychiatr Scand Suppl 358:67–71
Al-Fulaij MA, Ren Y, Beinborn M, Kopin AS (2007) Identification of amino acid determinants of dopamine 2 receptor synthetic agonist function. J Pharmacol Exp Ther 321:298–307
Karabulut AK, Pratten MK (1998) Species-specificity of growth-promoting effects of prolactin during rat embryogenesis. J Anat 192(Pt 1):1–12
Van der Graaf PH, Van Schaick EA, Math-ot RA, Ijzerman AP, Danhof M (1997) Mechanism-based pharmacokinetic–pharmacodynamic modeling of the effects of N6-cyclopentyladenosine analogs on heart rate in rat: estimation of in vivo operational affinity and efficacy at adenosine A1 receptors. J Pharmacol Exp Ther 283:809–816
Visser SA, Wolters FL, Gubbens-Stibbe JM, Tukker E, Van der Graaf PH, Peletier LA, Danhof M (2003) Mechanism-based pharmacokinetic/pharmacodynamic modeling of the electroencephalogram effects of GABAA receptor modulators: in vitro–in vivo correlations. J Pharmacol Exp Ther 304:88–101
Zuideveld KP, Van der Graaf PH, Newgreen D, Thurlow R, Petty N, Jordan P, Peletier LA, Danhof M (2004) Mechanism-based pharmacokinetic–pharmacodynamic modeling of 5-ht1a receptor agonists: estimation of in vivo affinity and intrinsic efficacy on body temperature in rats. J Pharmacol Exp Ther 308:1012–1020
Acknowledgments
Pfizer Global Research and Development, Sandwich, England, United Kingdom financially supported this work.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stevens, J., Ploeger, B.A., Hammarlund-Udenaes, M. et al. Mechanism-based PK–PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans. J Pharmacokinet Pharmacodyn 39, 463–477 (2012). https://doi.org/10.1007/s10928-012-9262-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10928-012-9262-4